BlueRock Therapeutics LP

Building a sustainable ecosystem requires more than just scientific excellence—it demands a coordinated approach to manufacturing, capital access, and talent development. The Centre for Commercializat

Founded eight years ago, Bayer subsidiary BlueRock Therapeutics is now putting the final touches to the late-stage program for bemdaneprocel, its closely watched investigational cell therapy for Parki

With a steep climb in second-quarter sales and just-released promising data in heart failure, Bayer AG 's mineralocorticoid receptor antagonist Kerendia is finally looking like a candidate to fill th

Current treatments for Parkinson's still only provide symptomatic relief but Bayer AG is hopeful that a couple of its cell and gene therapies being developed by its wholly owned subsidiaries BlueRo